Clinical Trial Update: Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing induction of response/remission and safety in moderate to severe Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Crohn Disease | Phase 3 | Status: TERMINATED